Immunocore Holdings(IMCR)
$29.94-0.54 (-1.76%)
IMCR
Immunocore Holdings stock drug pipeline
$29.94
At close:-0.54 (-1.76%)
Want to see IMCR full AI Analyst Report?
Immunocore Holdings (IMCR) Drug Pipeline
258 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Imc-P115c | Cancer, Hla-A*02:01-Positive, Prame Positive | Phase I | Recruiting | Study of IMC-P115C in Advanced PRAME-Positive Cancers | Aug 26, 2025 | ― |
| Imc-R117c, Chemotherapy Drug, Kinase Inhibitor, Antiangiogenic Agent, Monoclonal Antibody | Cancer, Hla-A*02:01-Positive | phase1AndPhase2 | Recruiting | Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers | Feb 05, 2025 | ― |
| Nivolumab, Nivolumab + Relatlimab, Brenetafusp | Advanced Melanoma | Phase III | Recruiting | IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) | Oct 19, 2023 | ― |
| Tebentafusp, Tebentafusp With Pembrolizumab, Investigators Choice | Advanced Melanoma | Phase III | Recruiting | Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) | Aug 26, 2022 | ― |
| Brenetafusp, Brenetafusp And Pembrolizumab, Brenetafusp And Chemotherapy, Brenetafusp And Monoclonal Antibodies And Chemotherapy, Brenetafusp And Tebentafusp, Brenetafusp And Bevacizumab, Brenetafusp And Kinase Inhibitors | Select Advanced Solid Tumors | phase1AndPhase2 | Recruiting | Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors | Jan 30, 2020 | ― |
| Pembrolizumab, Ipilimumab, Dacarbazine, Imcgp100 | Uveal Melanoma | Phase II | Active Not Recruiting | Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma | Feb 14, 2017 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Imc-P115c | Phase I | Cancer, Hla-A*02:01-Positive, Prame Positive | Recruiting | Study of IMC-P115C in Advanced PRAME-Positive Cancers | Aug 26, 2025 | ― |
| Imc-R117c, Chemotherapy Drug, Kinase Inhibitor, Antiangiogenic Agent, Monoclonal Antibody | phase1AndPhase2 | Cancer, Hla-A*02:01-Positive | Recruiting | Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers | Feb 05, 2025 | ― |
| Nivolumab, Nivolumab + Relatlimab, Brenetafusp | Phase III | Advanced Melanoma | Recruiting | IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) | Oct 19, 2023 | ― |
| Tebentafusp, Tebentafusp With Pembrolizumab, Investigators Choice | Phase III | Advanced Melanoma | Recruiting | Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) | Aug 26, 2022 | ― |
| Brenetafusp, Brenetafusp And Pembrolizumab, Brenetafusp And Chemotherapy, Brenetafusp And Monoclonal Antibodies And Chemotherapy, Brenetafusp And Tebentafusp, Brenetafusp And Bevacizumab, Brenetafusp And Kinase Inhibitors | phase1AndPhase2 | Select Advanced Solid Tumors | Recruiting | Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors | Jan 30, 2020 | ― |
| Pembrolizumab, Ipilimumab, Dacarbazine, Imcgp100 | Phase II | Uveal Melanoma | Active Not Recruiting | Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma | Feb 14, 2017 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Immunocore Holdings Plc (IMCR) have in its pipeline
Immunocore Holdings IMCR is currently developing the following drugs: Imc-P115c, Imc-R117c, Chemotherapy Drug, Kinase Inhibitor, Antiangiogenic Agent, Monoclonal Antibody, Nivolumab, Nivolumab + Relatlimab, Brenetafusp, Tebentafusp, Tebentafusp With Pembrolizumab, Investigators Choice, Brenetafusp, Brenetafusp And Pembrolizumab, Brenetafusp And Chemotherapy, Brenetafusp And Monoclonal Antibodies And Chemotherapy, Brenetafusp And Tebentafusp, Brenetafusp And Bevacizumab, Brenetafusp And Kinase Inhibitors, Pembrolizumab, Ipilimumab, Dacarbazine, Imcgp100. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

